Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans

Embracing Putative Induction of Dopamine Homeostasis

Bibliographic Data

ID15517158
AuthorsKenneth Blum (0000-0001-6727-803X, Eötvös Loránd University, corresponding author), Jag Khalsa (0000-0002-6534-3616, George Washington University), Jean Lud Cadet (0000-0001-5635-3524, National Institutes of Health), David Baron (0000-0001-7670-2613, Western University of Health Sciences), Abdalla Bowirrat (0000-0001-8185-0688, Reichman University), Brent Boyett (Wisconsin Department of Health Services), Lisa Lott (Christus Health), Raymond Brewer (Christus Health), Marjorie C Gondré‐Lewis (Howard University), Marjorie Gondré-Lewis, Gregory Bunt (Legacy Good Samaritan Medical Center), Shan Kazmi (Western University of Health Sciences), Mark S Gold (0000-0003-4713-3751, Washington University in St. Louis)
Year2021
Volume12
Pages623403-623403
Publication date2021-03-30
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2021.623403
PMID33868044
OpenAlexW3145498410
LanguageEN
Citations received2
References cited90

Over years, the regular use of cannabis has substantially increased among young adults, as indicated by the rise in cannabis use disorder (CUD), with an estimated prevalence of 8. 3% in the United States. Research shows that exposure to cannabis is associated with hypodopaminergic anhedonia (depression), cognitive decline, poor memory, inattention, impaired learning performance, reduced dopamine brain response-associated emotionality, and increased addiction severity in young adults. The addiction medicine community is increasing concern because of the high content of delta-9-tetrahydrocannabinol (THC) currently found in oral and vaping cannabis products, the cognitive effects of cannabis may become more pronounced in young adults who use these cannabis products. Preliminary research suggests that it is possible to induce 'dopamine homeostasis,' that is, restore dopamine function with dopamine upregulation with the proposed compound and normalize behavior in chronic cannabis users with cannabis-induced hypodopaminergic anhedonia (depression) and cognitive decline. This psychological, neurobiological, anatomical, genetic, and epigenetic research also could provide evidence to use for the development of an appropriate policy regarding the decriminalization of cannabis for recreational use

Addiction · Anhedonia · Cannabidiol · Cannabis · Cognition · Depression (economics · Dopamine · Effects of cannabis · Psychiatry · Bipolar Disorder and Treatment · Cannabis and Cannabinoid Research · Clinical Psychology · Medicine · Neuroscience · Prenatal Substance Exposure Effects · Psychology

Tools

Open DOIOpen Access